EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
The European Academy of Paediatrics has warned the EU to correct a new law that inadvertently prevents the provision of essential medical devices for children, citing unintended consequences of the EU Medical Devices Regulation (MDR).
In a letter sent on June 27, 2023 to EU Health Commissioner Stella Kyriakides, the Academy, along with 22 other medical associations, cited that the law that requires companies to recertify their products. Though the deadline for companies to achieve this has been extended until 2027/2028, reports from doctors claim that the new legislation has caused shortages of certain lifesaving equipment, especially those from small drug device companies that cannot afford the new compliance procedure, and that the extension has not solved the issue for these companies. All drug device companies are required by the new law to sign a contract by September 2024 with a notified body to begin the recertification process. The law came into effect in 2021 with the goal of preventing health scandals.
The group cited one particular company that received invoices from a notified body of over EUR €800,000 for a single device to be assessed. The device is already on the market for, at the most, 5 years of market access. At nearly 150 times more costly than the process in the United States for the same device, the group warns that similar situations may cause lifesaving drug devices to disappear from the market. In the letter, the associated groups urged for access protection of certain drug devices for children and patients with rare diseases. They reported that a specific type of catheter utilised in lifesaving surgery on newborns with heart defects has become unavailable due to the law, as well as shortages in dialysis machines for children with kidney disease.
The group emphasised the dire consequences of such shortages in their letter, stating “This will result in an avoidable risk of death and serious injury – not as a consequence of unsafe medical devices, but as a consequence of [the] disappearance of devices due to unforeseen effects of the EU Medical Devices Regulation.”
Source: EU must prevent medical devices for children from disappearing, say doctors groups [Accessed June 28, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/eu-must-prevent-medical-devices-children-disappearing-say-doctors-groups-2023-06-27/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...